SCHEMBL24333332

SCHEMBL24333332

COc1ccc(N2CCN(C)CC2)cc1S(N)(=O)=O

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.53
SIRT6 Q8N6T7 1/20 0.52
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PKM P14618 1/20 0.48
HTR6 P50406 2/20 0.47
MAPK1 P28482 2/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
MAPT P10636 2/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
ACHE P22303 1/20 0.44
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
RECQL P46063 1/20 0.44
PTK2B Q14289 1/20 0.44
FYN P06241 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31525467 0.89 SIRT6 (0.56) POLBSIRT6ALDH1A1PKMHTR6
SCHEMBL29469940 0.84 KMT2A (0.54) POLBALDH1A1PKMMAPK1MAPT
SCHEMBL31525646 0.82 PKM (0.45) SMN1; SMN2PKMMAPK1MAPTLMNA
SCHEMBL31525518 0.81 PKM (0.44) POLBALDH1A1PKMMAPK1MAPT
SCHEMBL31525876 0.79 MAPK1 (0.42) POLBALDH1A1SMN1; SMN2PKMMAPK1
SCHEMBL31525725 0.79 PKM (0.47) ALDH1A1PKMMAPK1GAA
SCHEMBL31525753 0.79 PKM (0.44) POLBALDH1A1PKMMAPK1RAB9A
SCHEMBL31525706 0.78 PKM (0.41) ALDH1A1SMN1; SMN2PKMMAPK1NPC1
SCHEMBL24333337 0.78 POLB (0.47) POLBSIRT6ALDH1A1SMN1; SMN2HTR6
SCHEMBL29469799 0.78 POLB (0.47) POLBSIRT6ALDH1A1SMN1; SMN2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122152-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-04-17 US disclosed
WO-2025068943-A1 KAT6 INHIBITORS BEIGENE SWITZERLAND GMBH (CH) 2025-04-03 WO disclosed
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-22 US disclosed
EP-4229048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER The Broad Institute, Inc. (US) 2023-08-23 EP disclosed
WO-2022081807-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed
WO-2022081807-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A POLB 566/4885SIRT6 20/4885ALDH1A1 985/4885
US-20250122152-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT7 POLB 883/4885SIRT6 23/4885ALDH1A1 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.